Want to see JP:3649 full AI Analyst Report?
FINDEX Inc. (3649) AI Stock Analysis
FINDEX Inc.
(TSE/TYO:3649)
The score is led by strong financial performance—high and improving margins, strong ROE, and a near debt-free balance sheet—with valuation further supported by a ~3.2% dividend yield and a moderate P/E. This is tempered by mixed technicals, including short-term weakness versus the 20-day average and low Stoch momentum despite a generally positive longer-term trend.
FINDEX Inc. (3649) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 20.91B
- Dividend Yield
- 3.15%
- Average Volume (3M)
- 72.47K
- Price to Earnings (P/E)
- 18.6
- Beta (1Y)
- 0.52
- Revenue Growth
- 6.39%
- EPS Growth
- 3.02%
- Country
- Japan
- Employees
- 325
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Healthcare Information Services
FINDEX Inc. Business Overview & Revenue Model
Company Description
FINDEX Inc., a company established in Tokyo in 1985, focuses on the creation, production, and distribution of medical technology systems across Japan. Their portfolio features Claio, a comprehensive medical imaging database management system utilized...
How the Company Makes Money
null
FINDEX Inc. Financial Statement Overview
Summary
Strong overall fundamentals driven by high and improving profitability (2025 operating margin ~29%, net margin ~21%) and a very conservative balance sheet with essentially no debt. Free cash flow quality is solid (FCF ~0.98x net income), but operating cash flow has been somewhat volatile and revenue growth has been uneven across years.
Income Statement
86Very PositiveBalance Sheet
92Very PositiveCash Flow
79Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.13B | 6.11B | 5.84B | 5.19B | 4.54B | 4.97B |
| Gross Profit | 4.02B | 3.98B | 3.55B | 3.33B | 2.72B | 2.56B |
| EBITDA | 2.02B | 2.09B | 1.83B | 1.78B | 1.32B | 1.25B |
| Net Income | 1.13B | 1.26B | 1.16B | 1.06B | 722.78M | 636.03M |
Balance Sheet | ||||||
| Total Assets | 6.92B | 6.81B | 6.69B | 5.94B | 4.98B | 4.56B |
| Cash, Cash Equivalents and Short-Term Investments | 2.47B | 1.68B | 1.73B | 2.69B | 2.41B | 2.17B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 20.00M |
| Total Liabilities | 1.24B | 1.34B | 1.08B | 1.09B | 939.06M | 1.04B |
| Stockholders Equity | 5.65B | 5.44B | 5.60B | 4.84B | 4.04B | 3.51B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 1.62B | 1.87B | 559.87M | 621.08M | 681.02M |
| Operating Cash Flow | 0 | 1.65B | 1.90B | 842.84M | 693.85M | 750.35M |
| Investing Cash Flow | 0 | -297.86M | -2.43B | -296.94M | -230.16M | -490.37M |
| Financing Cash Flow | 0 | -1.41B | -412.54M | -270.49M | -142.02M | -186.34M |
FINDEX Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3649, the sentiment is Neutral. The current price of 856.00 is below the 20-day moving average (MA) of 867.45, below the 50-day MA of 864.56, and above the 200-day MA of 840.97, indicating a neutral trend. The MACD of -2.45 indicates Positive momentum. The RSI at 45.78 is Neutral, neither overbought nor oversold. The STOCH value of 16.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:3649.
FINDEX Inc. Peers Comparison
Overall Rating
JP:241378.5Outperform- JP:364976Outperform
JP:393973Outperform
JP:448372Outperform
JP:448063Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:2413 | 79Outperform | JPY 1.25T | 26.80 | 11.45% | 1.20% | 15.76% | 13.53% |
| JP:3649 | 76Outperform | JPY 21.92B | 18.56 | ― | 3.15% | 6.39% | 3.02% |
| JP:3939 | 73Outperform | JPY 23.28B | 17.51 | ― | 1.83% | 13.74% | 30.76% |
| JP:4483 | 72Outperform | JPY 241.50B | 34.84 | ― | 0.49% | 18.89% | 11.66% |
| JP:4480 | 63Neutral | JPY 75.89B | 39.69 | 12.35% | ― | 24.03% | 34.50% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:3649 | FINDEX Inc. | 856.00 | 57.81 | 7.24% | |
| JP:2413 | M3 | 1840.50 | -299.63 | -14.00% | |
| JP:4480 | Medley, Inc. | 2386.00 | 280.00 | 13.30% | |
| JP:3939 | Kanamic Network Co., LTD. | 491.00 | 18.83 | 3.99% | |
| JP:4483 | JMDC Inc. | 3690.00 | -1186.28 | -24.33% |
FINDEX Inc. Corporate Events
FINDEX posts steady growth in key medical and public-sector software deployments
FINDEX Inc. reported preliminary implementation figures for its core healthcare and public-sector software products as of June 30, 2026, showing steady expansion in user institutions. Flagship data, document and archiving tools such as Claio, DocuMak...
FINDEX Issues Cautionary Notice on Q1 FY2026 Results Materials
FINDEX Inc. released supplementary information for its first-quarter fiscal 2026 business results, emphasizing that the materials are strictly for informational purposes and not a solicitation for any investment action. The company underscores that t...
FINDEX Posts Modest Q1 Growth, Lifts Dividend on Strong Balance Sheet
FINDEX Inc. posted a modest 2.0% year-on-year increase in first-quarter net sales to ¥1,989 million for the period ended March 31, 2026, while operating profit, ordinary profit and profit attributable to owners of parent all dipped slightly by a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026